Marc A Schneider
Overview
Explore the profile of Marc A Schneider including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
1450
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Janke F, Gasser M, Angeles A, Riediger A, Gortz M, Appenheimer L, et al.
J Exp Clin Cancer Res
. 2025 Mar;
44(1):87.
PMID: 40055810
Background: Outcomes under anti-PD-(L)1 therapy have been variable in advanced non-small cell lung cancer (NSCLC) without reliable predictive biomarkers so far. Targeted next-generation sequencing (NGS) of circulating tumor DNA (ctDNA)...
2.
Niedermaier B, Allgauer M, Muley T, Schneider M, Eichhorn M, Winter H, et al.
Thorac Cancer
. 2025 Jan;
16(1):e15536.
PMID: 39807578
Objective: Among the different subtypes of invasive lung adenocarcinoma, lepidic predominant adenocarcinoma (LPA) has been recognized as the lowest-risk subtype with good prognosis. The aim of this study is to...
3.
Milenkovic I, Cruciani S, Llovera L, Lucas M, Medina R, Pauli C, et al.
Mol Cell
. 2024 Dec;
85(1):177-190.e7.
PMID: 39662470
Mammalian ribosomal RNA (rRNA) molecules are highly abundant RNAs, decorated with over 220 rRNA modifications. Previous works have shown that some rRNA modification types can be dynamically regulated; however, how...
4.
Germline Polymorphisms Associated with Overall Survival in Lung Adenocarcinoma: Genome-Wide Analysis
Minnai F, Noci S, Esposito M, Schneider M, Kobinger S, Eichhorn M, et al.
Cancers (Basel)
. 2024 Oct;
16(19).
PMID: 39409885
Background/objectives: Lung cancer remains a global health concern, with substantial variation in patient survival. Despite advances in detection and treatment, the genetic basis for the divergent outcomes is not understood....
5.
Dernbach G, Kazdal D, Ruff L, Alber M, Romanovsky E, Schallenberg S, et al.
Eur J Cancer
. 2024 Sep;
211:114292.
PMID: 39276594
Introduction: Molecular profiling of lung cancer is essential to identify genetic alterations that predict response to targeted therapy. While deep learning shows promise for predicting oncogenic mutations from whole tissue...
6.
Gegner H, Naake T, Aljakouch K, Dugourd A, Kliewer G, Muller T, et al.
Clin Proteomics
. 2024 Jul;
21(1):49.
PMID: 38969985
Understanding the interplay of the proteome and the metabolome helps to understand cellular regulation and response. To enable robust inferences from such multi-omics analyses, we introduced and evaluated a workflow...
7.
Richtmann S, Marwitz S, Muley T, Koistinen H, Christopoulos P, Thomas M, et al.
Transl Res
. 2024 Mar;
272:177-189.
PMID: 38490536
Lung cancer has been shown to be targetable by novel immunotherapies which reactivate the immune system and enable tumor cell killing. However, treatment failure and resistance to these therapies is...
8.
Muley T, Herth F, Heussel C, Kriegsmann M, Thomas M, Meister M, et al.
Tumour Biol
. 2023 Oct;
46(s1):S219-S232.
PMID: 37840518
Background: Despite successful response to first line therapy, patients with small-cell lung cancer (SCLC) often suffer from early relapses and disease progression. Objective: To investigate the relevance of serum tumor...
9.
Rubio K, Muller J, Mehta A, Watermann I, Olchers T, Koch I, et al.
Discov Oncol
. 2023 Oct;
14(1):181.
PMID: 37787775
Background: Lung cancer (LC) causes more deaths worldwide than any other cancer type. Despite advances in therapeutic strategies, the fatality rate of LC cases remains high (95%) since the majority...
10.
Bozorgmehr F, Chung I, Christopoulos P, Krisam J, Schneider M, Bruckner L, et al.
BMC Cancer
. 2023 Aug;
23(1):740.
PMID: 37563548
No abstract available.